In addition, our study shows that combinatorial treatments of RTKi or PDGFRi and TMZ (the current standard of care treatment for GBM patients) might be beneficial for patients with tumors harboring ATRX mutations, which is in line with previous studies showing that TMZ inhibits glioma formation and increases the chemosensitivty of ATRX-deficient gliomas in vivo [33]. This evidence concerns the gene ATRX and glioblastoma.